Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression (PLoS One (2019) 14:2 (e0212254) DOI: 10.1371/journal.pone.0212254)

Abstract

  • The Supporting Information files were published with tracked changes. Please view the correct files below. Supporting information S1 Table. Baseline characteristics of the 91 Czech patients with biopsy-proven IgA nephropathy. (DOCX) S2 Table. Baseline characteristics of the three groups of the 91 Czech patients with biopsyproven IgA nephropathy (non-progressors, progressors, patients with ESRD). (DOCX) S3 Table. Analysis of a combined group of IgAN non-progressors and progressors vs. IgAN patients who reached ESRD. (DOCX) S4 Table. Median test (Mood test) comparing IgAN patients with end-stage renal disease reached during the follow-up vs. IgAN patients without ESRD for selected variables. (DOCX) S5 Table. Assessment of two groups (non-progressors [n = 70] and progressors [n = 7]) for the influence of E from the Oxford classification (MEST); other parameters (M, S, T) did not reach significance). (DOCX) S6 Table. Influence of Oxford classification MEST composite score in assessment of two groups (non-progressors [n = 70] and progressors [n = 7]). (DOCX) S7 Table. Mean values of selected laboratory parameters in a subset of patients treated with corticosteroids in group 1 with eGFR ?60 mL/min/1.73 m2 (n = 16) and group 2 with eGFR >60 mL/min/1.73 m2 (n = 24). (DOCX) S1 Fig. Discriminant analysis for three groups of IgAN patients (non-progressors in green, progressors in orange, ESRD in blue) and all parameters (eGFR, using MDRD formula (mL/min/1.73 m2); serum IgA (mg/mL); serum Gd-IgA1 (U/1 /g IgA; without neuraminidase); serum Gd-IgA1 (U/mL; without neuraminidase); serum Gd-IgA1 (U/1 /g IgA; with neuraminidase); serum Gd-IgA1 (U/mL; with neuraminidase). (DOCX) S2 Fig. Box-and-whiskers plots for progressors and non-progressors (group 1) vs. IgAN patients who reached ESRD during follow up (group 2) for selected parameters. (DOCX) S3 Fig. Receiver operating characteristic (ROC) curves for non-progressors vs. progressors. a- ROC curve for non-progressors vs. progressors using eGFR (MDRD, mL/min/1.73 m2), Gd-IgA1 biomarkers, and Oxford classification (individual parameters of Oxford MEST classification). Area under the curve, AUC = 0.936. b- Receiver operating characteristic (ROC) curve for non-progressors vs. progressors using eGFR (MDRD, mL/min/1.73 m2) and Oxford classification (individual parameters of Oxford MEST classification). Area under the curve, AUC = 0.836. (DOCX) S4 Fig. Receiver operator curve within two groups (eGFR, serum levels of IgG autoantibody specific for Gd-IgA1). Area under the curve = 1.00. Accuracy of the discrimination is 100%. Group 1 (n = 35), eGFR 60 mL/min/1.73 m2 at the time of renal-biopsy; group 2 (n = 42), eGFR >60 mL/min/1.73 m2 at the time of renal-biopsy. Prediction equation from logistic regression (predicts probability to choose group 1): Pred(group 1) = 1 / (1 + exp (-(1517.5–1.2E-02?AB-IgA-24.9?eGFR))). (DOCX) S5 Fig. Box-and-whiskers plots for selected variables within two groups. S-creat, serum creatinine (µmol/L); eGFR (MDRD, mL/min/1.73 m2); serum IgG autoantibody specific for Gd- IgA1 (U/mL). Group 1 (n = 35), eGFR ?60 mL/min/1.73 m2 at the time of renal biopsy; group 2 (n = 42), eGFR >60 mL/min/1.73 m2 at the time of renal biopsy. (DOCX).
  • Author List

  • Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J
  • Volume

  • 14